ArticleTranslational vision science & technology2026
Causal Relationship Between Blood Proteome and Retinitis Pigmentosa: A Mendelian Randomization Study.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Identification and validation of potential therapeutic targets for retinitis pigmentosa (RP). Methods: We utilized genome-wide significant protein quantitative trait locus (pQTL) data for 4719 plasma proteins derived from 35,559 individuals, alongside RP summary statistics from 126,454 individuals of European ancestry. The analysis employed several methods, including inverse variance weighted, weighted median, MR-Egger, and weighted mode, complemented by sensitivity analyses. Key proteins were validated through summary data-based Mendelian randomization (SMR) analysis and heterogeneity in dependent instruments (HEIDI) testing. Additionally, we constructed protein-protein interaction (PPI) networks, as well as Gene Ontology (GO) and functional enrichment analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Finally, the functions of the core proteins were validated through in vitro cellular experiments. Results: Mendelian randomization (MR) analysis identified 10 plasma proteins associated with RP. Acid phosphatase 6 (ACP6), adaptor-related protein complex 1 subunit gamma 2 (AP1G2), and annexin A2 (ANXA2) were confirmed as key candidate proteins through SMR and HEIDI testing. ACP6 and AP1G2 were linked to the mitigated phenotypic severity of RP, serving as protective factors, whereas ANXA2 was associated with an exacerbated of phenotypic severity of RP, indicating its potential role as a modulator of disease progression. Enrichment analysis revealed that these proteins participate in biological processes such as lipid metabolism, vesicle-mediated transport, and inflammatory responses. These experiments confirmed that overexpression of ACP6 or AP1G2 or knockdown of ANXA2 significantly inhibited H2O2-induced apoptosis and reactive oxygen species (ROS) accumulation in ARPE-19 cells. Conclusions: By integrating proteomic and genomic data and in vitro functional experiments, this study identified ACP6, AP1G2, and ANXA2 as potential therapeutic targets for RP. These findings provide a foundation for future drug development and offer new insights into the molecular mechanisms underlying RP. Translational Relevance: Identified causal proteins ACP6/AP1G2 and ANXA2 offer direct therapeutic targets for developing novel treatments to alleviate RP progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.